Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Active Biotech AB Identifier:
First received: January 9, 2007
Last updated: June 30, 2015
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 2, 2014